How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
内容由Sano Genetics提供。所有播客内容(包括剧集、图形和播客描述)均由 Sano Genetics 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Player FM -播客应用
使用Player FM应用程序离线!
使用Player FM应用程序离线!
EP 112: Making the leap: the scientists collaborating to transform genetic targets into next generation treatments, with David Ochoa
Manage episode 385370197 series 2631947
内容由Sano Genetics提供。所有播客内容(包括剧集、图形和播客描述)均由 Sano Genetics 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
This week on The Genetics Podcast Patrick is joined by David Ochoa, Platform Coordinator at Open Targets. They discuss how the Open Targets platform is enabling game-changing collaboration between academic research and big pharma. Working with partners including Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Genentech and Pfizer, Open Targets powers collaboration between some of the world’s biggest drug development pioneers and most renowned academic institutions with the goal of accelerating production of effective drug treatments.
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
04:33 The types of data sets used for target discovery
08:08 Managing the heterogeneity of data sets
13:29 David Ochoa's career trajectory, and entry into Open Targets
18:28 Addressability of diseases and targets by different modalities
22:24 Retrospective analysis of genetic evidence in drug approvals
36:58 Future focus on revamping Open Targets genetics
39:54 Exploring somatic variation and mutational scanning
42:49 Clinical trial stoppage
48:22 Closing remarks
187集单集
Manage episode 385370197 series 2631947
内容由Sano Genetics提供。所有播客内容(包括剧集、图形和播客描述)均由 Sano Genetics 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
This week on The Genetics Podcast Patrick is joined by David Ochoa, Platform Coordinator at Open Targets. They discuss how the Open Targets platform is enabling game-changing collaboration between academic research and big pharma. Working with partners including Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Genentech and Pfizer, Open Targets powers collaboration between some of the world’s biggest drug development pioneers and most renowned academic institutions with the goal of accelerating production of effective drug treatments.
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
04:33 The types of data sets used for target discovery
08:08 Managing the heterogeneity of data sets
13:29 David Ochoa's career trajectory, and entry into Open Targets
18:28 Addressability of diseases and targets by different modalities
22:24 Retrospective analysis of genetic evidence in drug approvals
36:58 Future focus on revamping Open Targets genetics
39:54 Exploring somatic variation and mutational scanning
42:49 Clinical trial stoppage
48:22 Closing remarks
187集单集
Όλα τα επεισόδια
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。